Brief: FDA Approves Awiqli First Once-Weekly Insulin For Type 2 Diabetes Mellitus In Pediatric Patients
23/10/2026 19:20
BRIEF-FDA Approves Awiqli First Once-Weekly Insulin For Type 2 Diabetes Mellitus In Pediatric Patients Oct 23 (Reuters) - FDA:
FDA: FDA APPROVES FIRST ONCE-WEEKLY INSULIN FOR TYPE 2 DIABETES MELLITUS IN PEDIATRIC PATIENTS
FDA: AWIQLI IS ADMINISTERED BY SUBCUTANEOUS (UNDER THE SKIN) INJECTION ONCE WEEKLY
Source text: [ID:]
Further company coverage: [NOVOb.CO]
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Novo Nordisk A/S
See all newsUS judge won't block Eli Lilly ads for weight-loss drugs, rules against Novo Nordisk (updated)
US judge lets Eli Lilly continue ads for weight-loss drugs, rules against Novo Nordisk
CVS is trying out pharmacists in chronic health management
Brief: FDA Approves Awiqli First Once-Weekly Insulin For Type 2 Diabetes Mellitus In Pediatric Patients
Dr Reddy's rolls out new generic Ozempic brands to ease Obeda supply hit